Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report.
Ayaka IsogaiHaruru KotaniMasataka SawakiMasaya HattoriAkiyo YoshimuraAyumi KataokaKazuki NozawaYuri OzakiYuka EndoAkira NakakamiRie KomakiHiroji IwataPublished in: Surgical case reports (2023)
This case suggests that trastuzumab monotherapy may be effective in certain patients with HER2-positive breast cancer. In the future, identifying patients who are more likely to respond to trastuzumab, as in this case, will allow for more options regarding de-escalation therapy without chemotherapy, particularly in elderly patients who are concerned about the side effects of chemotherapy.
Keyphrases
- positive breast cancer
- epidermal growth factor receptor
- end stage renal disease
- open label
- newly diagnosed
- metastatic breast cancer
- ejection fraction
- locally advanced
- chronic kidney disease
- combination therapy
- case report
- stem cells
- randomized controlled trial
- tyrosine kinase
- peritoneal dialysis
- clinical trial
- mesenchymal stem cells
- squamous cell carcinoma
- radiation therapy
- smoking cessation
- patient reported outcomes
- chemotherapy induced
- study protocol
- replacement therapy